|
Chelsea Therapeutics International |
|
|
3530 Toringdon Way, Suite 200
Charlotte, NC 28277 USA
phone:704 341 1516
fax:704 752 1479
|
|
| Symbol |
CHTP |
| Exchange |
NASDAQ |
| Founded |
2004 |
| Employees |
|
|
|
| www.chelseatherapeutics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| It is a biopharmaceutical company developing prescription products |
|
| Management |
| Simon Pedder, Ph.D., President and CEO; L. Arthur Hewitt, Ph.D., Chief Scientific Officer; J. Nick Riehle, M.B.A., Vice President, Administration and CFO; Keith Schmidt, M.B.A., Vice President, Marketing and Sales; Joseph Oliveto, M.B.A., Vice President, Operations |
| |
|
|
|
|
|
|
|
| Keywords |
| biopharmaceutical company, diseases, metabolically inert, psoriasis, droxidopa, norepinephrine |
|
|
|
| Description |
|
Chelsea Therapeutics International is a biopharmaceutical company developing prescription products in multiple therapeutic categories such as RA, psoriasis and other inflammatory conditions. These high-potential global opportunities are balanced by the development of the company�s orphan drug candidate Droxidopa, an oral therapeutic currently approved and marketed in Japan, for the treatment of neurogenic orthostatic hypotension. Chelsea is committed to creating value by building a world-class team, accelerating the development of its product candidates and expanding its therapeutic pipeline through acquisitions and alliances |
|
|
| Strategy |
Chelsea concentrates its efforts on acquiring and developing technologies for the treatment of rheumatoid arthritis (RA), psoriasis, cancer and other immunological disorders.
|
|
| Status |
| Early clinical data suggests that Chelsea's lead product candidate, CH-1504, may support a safe and effective treatment for rheumatoid arthritis and may have further applications for psoriasis, certain cancers and other immunological disorders. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
